Shots:

• The P-III study involves assessing JZP-258 vs PBO in 201 patients with narcolepsy + cataplexy prior treated with Xyrem- naive to Xyrem- or with/without anti-cataplectic treatments
• The P-III study results: met its 1EPs & 2EPs; reduction in no. of cataplexy attacks in a week and Epworth Sleepiness Scale score
• JZP-258 is an oxybate therapy targeting GABA_B receptor with a unique composition of cations resulting in 92% less sodium than Xyrem (sodium oxybate) and is evaluated for the treatment of cataplexy and excessive daytime sleepiness in narcolepsy & idiopathic hypersomnia. Jazz also plans to file NDA for JZP-258 based on above results

  Ref: Jazz Pharmaceuticals | Image: Studios Architecture